Myriad Genetics (MYGN) Under Pressure as Quest Diagnostics (DGX) Enters the BRCA Fray
Tweet Send to a Friend
Shares of Myriad Genetics (NASDAQ: MYGN) are getting clipped Tuesday (-4.5%) as Quest Diagnostics (NYSE: DGX) is encroaching on the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
